Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Duster340 on Oct 20, 2023 12:28pm

It Is Too Bad

my good friend davgro got left standing on the dock with his pants down while the good ship ATE steamed away. "clearly below in his post he got some bad advice and decided to push his own nonsense"  LMFAO

Post by davgroon Oct 03, 2023 1:07pm
112 Views 
Post# 35667226

Investors Avoiding "Risk-On" Stocks like ATE

RBC Capital Markets said recently that very few investors are currently looking to get aggressive in more "risk-on" stocks like clinical-stage biotech companies.  Unlike Healthcare and Pharma stocks that do well during an economic downturn these biotech companies have no revenue stream and negative cashflow.

There is definitely fear in the market and many investors are moving into cash since current yields are attractive.  Those who are thinking of adding to their ATE position or starting a new position have lots of time to make a decision before any study news is released in 2024.  Tax loss selling season is right around the corner and you could scoop up some cheap ATE shares near or at a new 52-week low.  There doesn't appear to be a rush on at the moment to buy ATE shares as evidenced by recent low daily volumes and low share price and considering no market moving news is due out until 2024..
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities